Style | Citing Format |
---|---|
MLA | Nabavi SM, et al.. "Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran." Vaccines, vol. 10, no. 1, 2022, pp. -. |
APA | Nabavi SM, Mehrabani M, Ghalichi L, Nahayati MA, Ghaffari M, Ashtari F, Mohammadianinejad SE, Karimi S, Faghani L, Yazdanbakhsh S, Najafian A, Shahpasand K, Vosough M (2022). Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran. Vaccines, 10(1), -. |
Chicago | Nabavi SM, Mehrabani M, Ghalichi L, Nahayati MA, Ghaffari M, Ashtari F, Mohammadianinejad SE, et al.. "Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran." Vaccines 10, no. 1 (2022): -. |
Harvard | Nabavi SM et al. (2022) 'Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran', Vaccines, 10(1), pp. -. |
Vancouver | Nabavi SM, Mehrabani M, Ghalichi L, Nahayati MA, Ghaffari M, Ashtari F, et al.. Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran. Vaccines. 2022;10(1):-. |
BibTex | @article{ author = {Nabavi SM and Mehrabani M and Ghalichi L and Nahayati MA and Ghaffari M and Ashtari F and Mohammadianinejad SE and Karimi S and Faghani L and Yazdanbakhsh S and Najafian A and Shahpasand K and Vosough M}, title = {Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran}, journal = {Vaccines}, volume = {10}, number = {1}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Nabavi SM AU - Mehrabani M AU - Ghalichi L AU - Nahayati MA AU - Ghaffari M AU - Ashtari F AU - Mohammadianinejad SE AU - Karimi S AU - Faghani L AU - Yazdanbakhsh S AU - Najafian A AU - Shahpasand K AU - Vosough M TI - Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran JO - Vaccines VL - 10 IS - 1 SP - EP - PY - 2022 ER - |